HRP20231654T1 - Supstituirani spojevi piridotriazina i njihove uporabe - Google Patents
Supstituirani spojevi piridotriazina i njihove uporabe Download PDFInfo
- Publication number
- HRP20231654T1 HRP20231654T1 HRP20231654TT HRP20231654T HRP20231654T1 HR P20231654 T1 HRP20231654 T1 HR P20231654T1 HR P20231654T T HRP20231654T T HR P20231654TT HR P20231654 T HRP20231654 T HR P20231654T HR P20231654 T1 HRP20231654 T1 HR P20231654T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- halogen
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
Links
- HHQDNOXLJMIISM-UHFFFAOYSA-N pyrido[3,2-d]triazine Chemical class C1=NN=NC2=CC=CN=C21 HHQDNOXLJMIISM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 54
- 229910052736 halogen Inorganic materials 0.000 claims 40
- 150000002367 halogens Chemical group 0.000 claims 40
- 150000003839 salts Chemical class 0.000 claims 36
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 19
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- OZAXFSZBUZLYAI-FZMZJTMJSA-N (10S,13S)-N-[(2,4-difluorophenyl)methyl]-13-(fluoromethyl)-6-hydroxy-10-methyl-5,8-dioxo-1,2,9-triazatricyclo[7.4.1.02,7]tetradeca-3,6,11-triene-4-carboxamide Chemical compound C[C@@H](C=C[C@@H](CF)N(C1)N(C=C(C(NCC(C=CC(F)=C2)=C2F)=O)C2=O)C3=C2O)N1C3=O OZAXFSZBUZLYAI-FZMZJTMJSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 102220465932 Beta-1,3-glucuronyltransferase LARGE2_R13A_mutation Human genes 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Claims (37)
1. Spoj, naznačen time, da je predstavljen Formulom I:
[image]
ili njegova farmaceutski prihvatljiva sol, u kojoj
Ar je C6-C10 aril ili šesteročlani do deseteročlani heteroaril koji sadrži jedan, dva ili tri heteroatoma odabrana od N, O i S; gdje su C6-C10 aril ili šesteročlani do deseteročlani heteroaril opcionalno supstituirani s 1-4 supstituenta neovisno odabrana iz skupine koju čine halogen, C1-C6 alkil, C1-C6 haloalkil, i C1-C6 alkiloksi;
R1 je H, C1-C3 alkil ili fenil;
R2 je H ili C1-C3 alkil;
R3 je H ili C1-C3 alkil;
svaki od R4 i R5 je neovisno H, halogen, cijano, C1-C6 alkil, C1-C6 alkiloksi, C6-C10 aril, ili šesteročlani do deseteročlani heteroaril koji sadrži jedan, dva ili tri heteroatoma odabrana od N, O i S; gdje su C1-C6 alkil, C1-C6 alkiloksi, C6-C10 aril, ili šesteročlani do deseteročlani heteroaril opcionalno supstituirani s jednom, dvije ili tri skupine neovisno odabrane od sljedećih: halogen, C1-C3 alkiloksi, ili C1-C3 haloalkiloksi; ili
R4 i R5 su spojeni zajedno za tvorbu 3-6-članog karbocikličkog prstena ili 4-6-članog heterocikličkog prstena koji sadrži jedan heteroatom odabran od N, O i S;
R6 je H, halogen, C1-C6 alkil, C1-C6 alkiloksi, ili C1-C6 haloalkil;
R7 je H, halogen, C1-C6 alkil, C1-C6 alkiloksi, ili C1-C6 haloalkil;
R8A i R8B su neovisno H, C1-C3 alkil ili benzil; i
-X-Y- je -(CR13AR13B)p-CR9=CR10-; gdje
R9 je H, halogen, C1-C6 alkil, C1-C6 haloalkil, ili C1-C6 alkiloksi;
R10 je H, halogen, C1-C6 alkil, C1-C6 haloalkil, ili C1-C6 alkiloksi; i
svaki od R13A i R13B je neovisno H, halogen, C1-C6 alkil, C1-C6 alkiloksi, ili C1-C6 haloalkil; i
p je 0 ili 1.
2. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je spoj predstavljen Formulom Ia:
[image]
ili time, da je spoj predstavljen Formulom Ib:
[image]
3. Spoj prema patentnom zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time, da Ar je C6-C10 aril ili šesteročlani do deseteročlani heteroaril koji sadrži jedan heteroatom odabran od N, O i S; gdje su C6-C10 aril ili šesteročlani do deseteročlani heteroaril opcionalno supstituirani s
(a) 1-4 supstituenta neovisno odabrana iz skupine koju čine halogen, C1-C6 alkil, i C1-C6 alkiloksi; ili
(b) 1-4 halogena; ili
(c) 1-3 supstituenta neovisno odabrana od Cl i F.
4. Spoj prema bilo kojem od patentnih zahtjeva 1-3, ili njegova farmaceutski prihvatljiva sol, naznačen time, da Ar je skupina predstavljena Formulom:
[image]
u kojoj Z je N ili CRA; n je 0, 1, 2, 3 ili 4; i svaki RA je neovisno halogen, C1-C6 alkil, i C1-C6 alkiloksi, opcionalno gdje Z je CH ili N.
5. Spoj prema bilo kojem od patentnih zahtjeva 1-4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da Ar je:
[image]
n je 1, 2, 3 ili 4; i svaki RA je
(a) neovisno odabran od halogena i C1-C6 alkiloksi; ili
(b) neovisno halogen ili -O-C1-4 alkil.
6. Spoj prema bilo kojem od patentnih zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol, naznačen time, da Ar je:
[image]
7. Spoj prema bilo kojem od patentnih zahtjeva 1-4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da Ar je:
[image]
n je 1, 2 ili 3; i svaki RA je neovisno fluor ili klor.
8. Spoj prema bilo kojem od patentnih zahtjeva 1-4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima Formulu II:
[image]
u kojoj
n je 0, 1, 2, 3 ili 4; i
svaki RA je neovisno halogen, C1-C6 alkil, i C1-C6 alkiloksi.
9. Spoj prema bilo kojem od patentnih zahtjeva 1-5 i 8, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima Formulu IIa:
[image]
u kojoj
n je 0, 1, 2, 3 ili 4; i
svaki RA je neovisno halogen, C1-C6 alkil, i C1-C6 alkiloksi; ili
time, da spoj ima Formulu IIb:
[image]
u kojoj
n je 0, 1, 2, 3 ili 4; i
svaki RA je neovisno halogen, C1-C6 alkil, i C1-C6 alkiloksi.
10. Spoj prema bilo kojem od patentnih zahtjeva 1-9, ili njegova farmaceutski prihvatljiva sol, naznačen time, da
(a) -X-Y- je -CR13AR13B-CR9=CR10-; ili
(b) -X-Y- je -CH2-CR9=CR10-; ili
(c) -X-Y- je -CR9=CR10-.
11. Spoj prema bilo kojem od patentnih zahtjeva 1-10, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R9 je H ili halogen; i R10 je H ili halogen.
12. Spoj prema bilo kojem od patentnih zahtjeva 1-11, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima Formulu IV:
[image]
u kojoj z je 0 ili 1.
13. Spoj prema bilo kojem od patentnih zahtjeva 1-12, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima Formulu IVa:
[image]
u kojoj z je 0 ili 1; ili
time, da spoj ima Formulu IVb:
[image]
u kojoj z je 0 ili 1.
14. Spoj prema bilo kojem od patentnih zahtjeva 1-13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da svaki od R9 i R10 je neovisno H, halogen, C1-C6 alkil, ili C1-C6 haloalikl.
15. Spoj prema patentnom zahtjevu 12, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
z je 0;
svaki od R1, R2 i R3 je H;
R4 i R5 su neovisno H, halogen, cijano, C1-C6 alkil, C1-C6 alkiloksi, C6-C10 aril, ili šesteročlani do deseteročlani heteroaril koji sadrži jedan, dva ili tri heteroatoma odabrana od N, O i S;
R6 i R7 su neovisno H, halogen, C1-C6 alkil, C1-C6 alkiloksi, ili C1-C6 haloalkil;
oba R8A i R8B su H;
svaki od R9 i R10 je neovisno H, halogen, C1-C6 alkil, ili C1-C6 haloalkil;
svaki RA je neovisno fluor ili klor; i
n je 1, 2 ili 3.
16. Spoj prema patentnom zahtjevu 12, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
z je 0;
svaki od R1, R2 i R3 je H;
R4 i R5 su neovisno H, halogen, cijano, C1-C6 alkil, ili C1-C6 alkiloksi;
R6 i R7 su neovisno H, halogen, C1-C6 alkil, C1-C6 alkiloksi, ili C1-C6 haloalkil;
oba R8A i R8B su H;
svaki od R9 i R10 je neovisno H, halogen, C1-C6 alkil, ili C1-C6 haloalkil;
svaki RA je neovisno fluor ili klor; i
n je 1, 2 ili 3.
17. Spoj prema patentnom zahtjevu 12, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
z je 0;
svaki od R1, R2 i R3 je H;
R4 i R5 su neovisno H, halogen, ili C1-C6 alkil;
R6 i R7 su neovisno H, halogen, ili C1-C6 alkil;
oba R8A i R8B su H;
svaki od R9 i R10 je neovisno H, halogen, ili C1-C6 alkil;
svaki RA je neovisno fluor ili klor; i
n je 1, 2 ili 3.
18. Spoj prema bilo kojem od patentnih zahtjeva 1-17, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R8B je H.
19. Spoj prema bilo kojem od patentnih zahtjeva 1-18, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R8A je H.
20. Spoj prema bilo kojem od patentnih zahtjeva 1-19, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3 je H.
21. Spoj prema bilo kojem od patentnih zahtjeva 1-19, ili njegova farmaceutski prihvatljiva sol, naznačen time, da oba R1 i R2 su H.
22. Spoj prema bilo kojem od patentnih zahtjeva 1-21, ili njegova farmaceutski prihvatljiva sol, naznačen time, da
(a) svaki od R4 i R5 je neovisno H, ili C1-C6 alkil, gdje je C1-C6 alkil opcionalno supstituiran s jednom, dvije ili tri skupine neovisno odabrane od halogena, C1-C3 alkiloksi, ili C1-C3 haloalkiloksi; ili
(b) R4 je H ili C1-C6 alkil, gdje je C1-C6 alkil opcionalno supstituiran s jednom, dvije ili tri skupine neovisno odabrane od halogena, C1-C3 alkiloksi, ili C1-C3 haloalkiloksi; i R5 je H ili C1-C6 alkil; ili
(c) R4 je H ili C1-C6 alkil, gdje je C1-C6 alkil opcionalno supstituiran s jednom, dvije ili tri skupine neovisno odabrane od halogena, C1-C3 alkiloksi, ili C1-C3 haloalkiloksi; i R5 je H; ili
(d) R4 i R5 su neovisno H, Me, OMe, ili -CH2F; ili
(e) R4 i R5 su spojeni zajedno za tvorbu 4-6-članog heterocikličkog prstena koji sadrži jedan heteroatom odabran od N, O i S.
23. Spoj prema bilo kojem od patentnih zahtjeva 1-21, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R6 je
(a) H, halogen, C1-C6 alkil, ili C1-C6 haloalkil;
(b) H, C1-C6 alkil, ili C1-C6 haloalkil;
(c) H, metil, ili CH2F;
(d) H, halogen, ili C1-C6 alkil;
(e) halogen, ili C1-C6 alkil;
(f) C1-C6 alkil;
(g) metil; ili
(h) H.
24. Spoj prema bilo kojem od patentnih zahtjeva 1-23, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R7 je
(a) H, halogen, C1-C6 alkil, ili C1-C6 haloalkil;
(b) H, halogen, ili C1-C6 alkil;
(c) halogen, ili C1-C6 alkil;
(d) C1-C6 alkil; ili
(e) H.
25. Spoj prema bilo kojem od patentnih zahtjeva 1-24, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je svaki od R13A i R13B neovisno
(a) H, halogen, C1-C6 alkil, ili C1-C6 alkiloksi; ili
(b) H, halogen, ili C1-C6 haloalkil; ili
(c) H, halogen, ili metoksi; ili
(d) H, fluor, ili metoksi.
26. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj je (1S,2R,5S)-8-hidroksi-2,5-dimetil-7,9-diokso-N-(2,4,6-trifluorobenzil)-2,5,7,9-tetrahidro-1,6-metanopirido[1,2-b][1,2,5]triazonin-10-karboksamid.
27. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj je (1S,2S,5S)-8-hidroksi-2,5-dimetil-7,9-diokso-N-(2,4,6-trifluorobenzil)-2,5,7,9-tetrahidro-1,6-metanopirido[1,2-b][1,2,5]triazonin-10-karboksamid.
28. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj je (1S,2R,5S)-N-(2,4-difluorbenzil)-8-hidroksi-2,5-dimetil-7,9-diokso-2,5,7,9-tetrahidro-1,6-metanopirido[1,2-b][1,2,5]triazonin-10-karboksamid.
29. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj je (1S,2S,5S)-N-(2,4-difluorbenzil)-8-hidroksi-2,5-dimetil-7,9-diokso-2,5,7,9-tetrahidro-1,6-metanopirido[1,2-b][1,2,5]triazonin-10-karboksamid.
30. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj je (2S,5S)-N-(2,4-difluorbenzil)-2-(fluorometil)-8-hidroksi-5-metil-7,9-diokso-2,5,7,9-tetrahidro-1,6-metanopirido[1,2-b][1,2,5]triazonin-10-karboksamid.
31. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj je (1S,2R,5S)-N-(3-kloro-2,4-difluorbenzil)-8-hidroksi-2,5-dimetil-7,9-diokso-2,5,7,9-tetrahidro-1,6-metanopirido[1,2-b][1,2,5]triazonin-10-karboksamid.
32. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj je (1S,2R,5S)-2-etil-8-hidroksi-5-metil-7,9-diokso-N-(2,4,6-trifluorobenzil)-2,5,7,9-tetrahidro-1,6-metanopirido[1,2-b][1,2,5]triazonin-10-karboksamid.
33. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj je (1S,2S,5S)-2-(fluorometil)-8-hidroksi-5-metil-7,9-diokso-N-(2,4,6-trifluorobenzil)-2,5,7,9-tetrahidro-1,6-metanopirido[1,2-b][1,2,5]triazonin-10-karboksamid.
34. Farmaceutski pripravak, naznačen time, da sadrži terapeutski učinkovitu količinu spoja u skladu s bilo kojim od patentnih zahtjeva 1-33, ili njegove farmaceutski prihvatljive soli, i farmaceutski prihvatljivo pomoćno sredstvo.
35. Spoj prema bilo kojem od patentnih zahtjeva 1-33, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema patentnom zahtjevu 34, naznačen time, da je za uporabu u medicinskom liječenju.
36. Spoj prema bilo kojem od patentnih zahtjeva 1-33, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema patentnom zahtjevu 34, naznačen time, da je za uporabu u liječenju HIV infekcije.
37. Spoj za uporabu prema patentnom zahtjevu 36, naznačen time, da je spoj za uporabu putem oralne, intravenozne, supkutane ili intramuskularne primjene.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163139237P | 2021-01-19 | 2021-01-19 | |
| US202163190461P | 2021-05-19 | 2021-05-19 | |
| EP22704452.6A EP4196479B1 (en) | 2021-01-19 | 2022-01-18 | Substituted pyridotriazine compounds and uses thereof |
| PCT/US2022/012773 WO2022159387A1 (en) | 2021-01-19 | 2022-01-18 | Substituted pyridotriazine compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231654T1 true HRP20231654T1 (hr) | 2024-03-15 |
Family
ID=80514578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231654TT HRP20231654T1 (hr) | 2021-01-19 | 2022-01-18 | Supstituirani spojevi piridotriazina i njihove uporabe |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11613546B2 (hr) |
| EP (2) | EP4196479B1 (hr) |
| JP (1) | JP2024503116A (hr) |
| KR (1) | KR20230134529A (hr) |
| AU (1) | AU2022210247A1 (hr) |
| CA (1) | CA3202957A1 (hr) |
| CL (1) | CL2023002074A1 (hr) |
| CO (1) | CO2023009518A2 (hr) |
| CR (1) | CR20230315A (hr) |
| DK (1) | DK4196479T3 (hr) |
| DO (1) | DOP2023000139A (hr) |
| FI (1) | FI4196479T3 (hr) |
| HR (1) | HRP20231654T1 (hr) |
| HU (1) | HUE064467T2 (hr) |
| IL (1) | IL304222A (hr) |
| LT (1) | LT4196479T (hr) |
| PE (1) | PE20231297A1 (hr) |
| PL (1) | PL4196479T3 (hr) |
| PT (1) | PT4196479T (hr) |
| SI (1) | SI4196479T1 (hr) |
| TW (1) | TWI824384B (hr) |
| WO (1) | WO2022159387A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4196479B1 (en) * | 2021-01-19 | 2023-11-01 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| PL1628685T3 (pl) | 2003-04-25 | 2011-05-31 | Gilead Sciences Inc | Przeciwwirusowe analogi fosfonianowe |
| DK1778251T3 (da) | 2004-07-27 | 2011-07-18 | Gilead Sciences Inc | Nukleosidphosphatkonjugater som anti-HIV-midler |
| JP5317257B2 (ja) | 2005-02-21 | 2013-10-16 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体 |
| KR101848819B1 (ko) | 2005-04-28 | 2018-04-16 | 비이브 헬쓰케어 컴퍼니 | Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체 |
| JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物 |
| EP1910363A4 (en) | 2005-08-04 | 2010-05-26 | Glaxosmithkline Llc | INHIBITORS OF HIV INTEGRASE |
| ES2569357T3 (es) | 2005-10-27 | 2016-05-10 | Shionogi & Co., Ltd. | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora sobre integrasa de HIV |
| EP1942736A2 (en) | 2005-10-27 | 2008-07-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
| TW200811153A (en) | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| AU2007275816A1 (en) | 2006-07-17 | 2008-01-24 | Merck Sharp & Dohme Corp. | 1-hydroxy naphthyridine compounds as anti-HIV agents |
| US20100216834A1 (en) | 2006-10-18 | 2010-08-26 | Isaacs Richard C A | Hiv integrase inhibitors |
| NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| CN103254138A (zh) | 2008-01-08 | 2013-08-21 | 默沙东公司 | 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法 |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2009154870A1 (en) | 2008-05-05 | 2009-12-23 | Merck & Co., Inc. | Hiv integrase inhibitors |
| CA2729649A1 (en) | 2008-07-02 | 2010-01-07 | Avexa Limited | Thiazopyrimidinones and uses thereof |
| DK2320908T3 (en) | 2008-07-25 | 2014-03-10 | Viiv Healthcare Co | DOLUTEGRAVIR prodrugs |
| WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| KR101772610B1 (ko) | 2008-07-25 | 2017-09-12 | 비이브 헬쓰케어 컴퍼니 | 화합물 |
| EP2465858B1 (en) | 2008-07-25 | 2013-12-25 | VIIV Healthcare Company | Process for preparing a pyrido[1,2-a]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamide derivative |
| WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| CN102239172A (zh) | 2008-10-06 | 2011-11-09 | 默沙东公司 | Hiv整合酶抑制剂 |
| PL2364314T3 (pl) | 2008-12-09 | 2014-08-29 | Gilead Sciences Inc | Modulatory receptorów Toll-podobnych |
| BRPI0923217A2 (pt) | 2008-12-11 | 2017-05-23 | Glaxosmithkline Llc | processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica. |
| CA2750045A1 (en) | 2009-01-28 | 2010-08-05 | Merck Sharp & Dohme Corp. | Bridged compounds as hiv integrase inhibitors |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| PT2444400T (pt) | 2009-06-15 | 2018-06-06 | Shionogi & Co | Derivado de carbamoilpiridona policíclico substituído |
| WO2011011483A1 (en) | 2009-07-22 | 2011-01-27 | Glaxosmithkline Llc | Chemical compounds |
| US20120220571A1 (en) | 2009-08-26 | 2012-08-30 | Wai John S | Hiv integrase inhibitors |
| CN102574854B (zh) | 2009-10-13 | 2014-04-16 | 伊兰科动物健康爱尔兰有限公司 | 大环整合酶抑制剂 |
| EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
| BR112012021595A2 (pt) | 2010-02-26 | 2017-02-21 | Japan Tobacco Inc | "composto derivado de 1,3,4,8-tetra-hidro-2h-pirido[1,2-a]pirazina, suas composições, seus usos, agente anti-hiv, inibidor da integrase de hiv e embalagem comercial" |
| US8716293B2 (en) | 2010-04-02 | 2014-05-06 | Janssen R&D Ireland | Macrocyclic integrase inhibitors |
| US9216995B2 (en) | 2010-04-12 | 2015-12-22 | Shionogi & Co., Ltd. | Pyridone derivative having integrase inhibitory activity |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| AP2013006707A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds |
| CN103140474A (zh) | 2010-07-02 | 2013-06-05 | 吉里德科学公司 | 治疗aids的萘-2-基乙酸衍生物 |
| ES2710609T3 (es) | 2010-08-05 | 2019-04-26 | Shionogi & Co | Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV |
| TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| AU2011320651A1 (en) | 2010-10-29 | 2013-05-02 | Merck Canada Inc. | HIV integrase inhibitors |
| US8835411B2 (en) | 2010-12-10 | 2014-09-16 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| KR20140027295A (ko) | 2011-04-21 | 2014-03-06 | 길리애드 사이언시즈, 인코포레이티드 | 벤조티아졸 화합물 및 이들의 약학적 용도 |
| ES2553449T3 (es) | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| JP6163428B2 (ja) | 2011-10-12 | 2017-07-12 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| JP6144698B2 (ja) | 2011-12-20 | 2017-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｉｖ複製の阻害剤としての縮合三環式化合物 |
| MX2014005002A (es) | 2012-04-20 | 2014-07-09 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih. |
| WO2014004279A1 (en) | 2012-06-25 | 2014-01-03 | Sunpower Corporation | Brace for solar module array |
| WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| US20150166520A1 (en) | 2012-07-20 | 2015-06-18 | Merck Sharp & Dohme Corp. | Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| DE102012220513B4 (de) | 2012-11-12 | 2023-02-16 | Bayerische Motoren Werke Aktiengesellschaft | Verfahren und Vorrichtung zur Herstellung eines Druckgussteils |
| WO2014099586A1 (en) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| SI3608325T1 (sl) | 2012-12-21 | 2022-09-30 | Gilead Sciences, Inc. | Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba |
| KR20150102069A (ko) | 2012-12-27 | 2015-09-04 | 니뽄 다바코 산교 가부시키가이샤 | 치환된 스피로피리도[1,2-a]피라진 유도체 및 그의 HIV 인테그라제 저해제로서의 의약 용도 |
| US9493479B2 (en) | 2013-04-16 | 2016-11-15 | Merck Sharp & Dohme Corp. | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors |
| SI2997033T1 (en) | 2013-05-17 | 2018-04-30 | Merck Sharp & Dohme Corp. | FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS |
| US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| WO2015006731A1 (en) | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
| NO2865735T3 (hr) | 2013-07-12 | 2018-07-21 | ||
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| JP6081662B2 (ja) | 2013-09-27 | 2017-02-15 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体 |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| NO2717902T3 (hr) | 2014-06-20 | 2018-06-23 | ||
| EP3196201B1 (en) | 2014-08-22 | 2021-04-28 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
| BR112017003663A2 (pt) | 2014-08-27 | 2017-11-28 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, método para tratamento de infecção por hiv. |
| WO2016094198A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2016090545A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| US10081647B2 (en) | 2015-03-26 | 2018-09-25 | Merck Sharp & Dohme Corp. | Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors |
| ES2837383T3 (es) | 2015-04-02 | 2021-06-30 | Gilead Sciences Inc | Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| WO2017087256A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors |
| EP3377066B1 (en) | 2015-11-17 | 2021-04-07 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
| US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| WO2017223280A2 (en) | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| CN110062627A (zh) | 2016-12-02 | 2019-07-26 | 默沙东公司 | 可用作hiv整合酶抑制剂的三环杂环化合物 |
| WO2018109786A1 (en) | 2016-12-16 | 2018-06-21 | Cipla Limited | Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives |
| US10786488B2 (en) | 2017-01-26 | 2020-09-29 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as HIV integrase inhibitors |
| BR112020005489A2 (pt) | 2017-09-22 | 2020-09-24 | Jubilant Epipad Llc, | composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer |
| WO2019160883A1 (en) | 2018-02-13 | 2019-08-22 | Cool Vapor Solutions | Methods and compositions for humidification and cooling of gas streams |
| US11413292B2 (en) * | 2018-02-15 | 2022-08-16 | Merck, Sharp & Dohme LLC | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| BR112020021768A2 (pt) | 2018-04-27 | 2021-01-26 | Merck Sharp & Dohme Corp. | compostos heterocíclicos tricíclicos úteis como inibidores de hiv-integrase |
| CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| PE20210477A1 (es) | 2018-05-31 | 2021-03-11 | Shionogi & Co | Derivado policiclico de carbamoilpiridona |
| EP3802543A1 (en) | 2018-05-31 | 2021-04-14 | F. Hoffmann-La Roche AG | Therapeutic compounds |
| MA52802A (fr) | 2018-05-31 | 2021-04-14 | Shionogi & Co | Dérivé de pyridone polycyclique |
| WO2019236396A1 (en) | 2018-06-05 | 2019-12-12 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020004443A1 (ja) | 2018-06-27 | 2020-01-02 | 国立大学法人北海道大学 | 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤 |
| CA3117453A1 (en) | 2018-10-22 | 2020-04-30 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| EP3886863A4 (en) | 2018-11-29 | 2023-01-04 | Board of Regents of the University of Nebraska | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF |
| MX2021011394A (es) | 2019-03-22 | 2021-10-13 | Gilead Sciences Inc | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico. |
| CN113795491A (zh) | 2019-04-30 | 2021-12-14 | 上海拓界生物医药科技有限公司 | 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途 |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| WO2021093846A1 (zh) | 2019-11-13 | 2021-05-20 | 上海拓界生物医药科技有限公司 | 新型四环杂环化合物及其药物用途 |
| WO2021107065A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | 多環性ピリドピラジン誘導体 |
| US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| CN116390924A (zh) | 2020-09-30 | 2023-07-04 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
| EP4196479B1 (en) * | 2021-01-19 | 2023-11-01 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| CN117083282A (zh) | 2021-02-16 | 2023-11-17 | 默沙东有限责任公司 | 可用作hiv整合酶抑制剂的四环杂环化合物 |
-
2022
- 2022-01-18 EP EP22704452.6A patent/EP4196479B1/en active Active
- 2022-01-18 EP EP23205202.7A patent/EP4321217A3/en active Pending
- 2022-01-18 LT LTEPPCT/US2022/012773T patent/LT4196479T/lt unknown
- 2022-01-18 KR KR1020237027739A patent/KR20230134529A/ko active Search and Examination
- 2022-01-18 CA CA3202957A patent/CA3202957A1/en active Pending
- 2022-01-18 PT PT227044526T patent/PT4196479T/pt unknown
- 2022-01-18 DK DK22704452.6T patent/DK4196479T3/da active
- 2022-01-18 FI FIEP22704452.6T patent/FI4196479T3/fi active
- 2022-01-18 PL PL22704452.6T patent/PL4196479T3/pl unknown
- 2022-01-18 WO PCT/US2022/012773 patent/WO2022159387A1/en active Application Filing
- 2022-01-18 HU HUE22704452A patent/HUE064467T2/hu unknown
- 2022-01-18 US US17/578,020 patent/US11613546B2/en active Active
- 2022-01-18 SI SI202230013T patent/SI4196479T1/sl unknown
- 2022-01-18 HR HRP20231654TT patent/HRP20231654T1/hr unknown
- 2022-01-18 PE PE2023002101A patent/PE20231297A1/es unknown
- 2022-01-18 TW TW111102065A patent/TWI824384B/zh active
- 2022-01-18 AU AU2022210247A patent/AU2022210247A1/en active Pending
- 2022-01-18 JP JP2023543136A patent/JP2024503116A/ja active Pending
- 2022-01-18 CR CR20230315A patent/CR20230315A/es unknown
-
2023
- 2023-02-03 US US18/164,317 patent/US11897892B2/en active Active
- 2023-07-03 IL IL304222A patent/IL304222A/en unknown
- 2023-07-17 DO DO2023000139A patent/DOP2023000139A/es unknown
- 2023-07-17 CO CONC2023/0009518A patent/CO2023009518A2/es unknown
- 2023-07-17 CL CL2023002074A patent/CL2023002074A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023009518A2 (es) | 2023-07-21 |
| EP4321217A3 (en) | 2024-04-10 |
| JP2024503116A (ja) | 2024-01-24 |
| AU2022210247A1 (en) | 2023-08-17 |
| EP4321217A2 (en) | 2024-02-14 |
| SI4196479T1 (sl) | 2024-01-31 |
| US11897892B2 (en) | 2024-02-13 |
| IL304222A (en) | 2023-09-01 |
| CA3202957A1 (en) | 2022-07-28 |
| CR20230315A (es) | 2023-09-01 |
| EP4196479B1 (en) | 2023-11-01 |
| TWI824384B (zh) | 2023-12-01 |
| DOP2023000139A (es) | 2023-08-15 |
| EP4196479A1 (en) | 2023-06-21 |
| PL4196479T3 (pl) | 2024-03-18 |
| LT4196479T (lt) | 2023-12-11 |
| US20230257389A1 (en) | 2023-08-17 |
| US20220267343A1 (en) | 2022-08-25 |
| TW202237128A (zh) | 2022-10-01 |
| PE20231297A1 (es) | 2023-08-22 |
| FI4196479T3 (fi) | 2024-01-17 |
| HUE064467T2 (hu) | 2024-03-28 |
| WO2022159387A1 (en) | 2022-07-28 |
| US11613546B2 (en) | 2023-03-28 |
| DK4196479T3 (da) | 2024-01-22 |
| KR20230134529A (ko) | 2023-09-21 |
| CL2023002074A1 (es) | 2024-01-12 |
| PT4196479T (pt) | 2024-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20191901T1 (hr) | Ciklizirani derivati sulfamoilarilamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20210813T1 (hr) | Piridinonpiridinilni spojevi supstituirani s metil/fluorpiridinilmetoksi i piridinonpiridinilni spojevi supstituirani s fluorpirimidinilmetoksi | |
| MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| AR081830A1 (es) | Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos | |
| RU2015109132A (ru) | Пролекарственная форма тенофовира и ее фармацевтические применения | |
| HRP20161428T1 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
| JP2017537949A5 (hr) | ||
| JP2015505296A5 (hr) | ||
| JP2019518046A5 (hr) | ||
| HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
| RS52862B (en) | IMIDASO [1,2-A] Pyridine Compounds as Tyrosine Kinase Receptor Inhibitors | |
| JP2016530259A5 (hr) | ||
| RU2012110246A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| JP2016506962A5 (hr) | ||
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR037371A1 (es) | Compuesto macrolida, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento | |
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| HRP20211405T1 (hr) | Supstituirani benzofuran, benzopirol, benzotiofen i strukturno povezani dopunski inhibitori | |
| JP2020511547A5 (hr) | ||
| HRP20212020T1 (hr) | Derivati parazola zgušenog prstena i njihova priprema i njihova primjena u liječenju raka, upale i imunoloških bolesti | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo |